Dare Bioscience, Inc. (DARE) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Dare Bioscience, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.313 Ladies and gentlemen, thank you for standing by. 00:00:02.313 -- 00:00:07.617 Hello and welcome to the conference call hosted by DARE Bioscience to review 00:00:07.617 -- 00:00:13.723 the company's first quarter 2026 financial results and to provide a business update. 00:00:13.723 -- 00:00:18.607 This call is being recorded. My name is King and I will be your operator today. 00:00:18.607 -- 00:00:23.751 With us today from DARE are Sabrina Martucci-Johnson, President 00:00:23.751 -- 00:00:29.136 and Chief Executive Officer, and Marty Herring-Layton, Chief Accounting 00:00:29.136 -- 00:00:31.875 Officer, Ms. Herring-Layton, please proceed. 00:00:31.875 -- 00:00:33.540 Ms. 00:00:33.540 -- 00:00:37.851 Good afternoon, and welcome to the DARE Bioscience Financial Results and Business Update 00:00:37.851 -- 00:00:41.415 Call for the quarter ended March 31, 2026. 00:00:41.493 -- 00:00:45.757 Today we will review our financial results, provide updates on our clinical pipeline, 00:00:45.757 -- 00:00:49.360 and discuss the continued execution of our expanded business strategy. 00:00:49.360 -- 00:00:54.846 That strategy includes a dual path approach, commercializing proprietary formulations 00:00:54.846 -- 00:01:00.331 through 503 compounding while pursuing FDA approval, and advancing select solutions 00:01:00.331 -- 00:01:04.355 as branded consumer health products that do not require a prescription. 00:01:04.355 -- 00:01:08.819 In all cases, our goal is to bring innovative women's health solutions to market as efficiently 00:01:08.819 -- 00:01:13.363 and quickly as possible. I would like to remind you that today's discussion will include 00:01:13.363 -- 00:01:17.267 forward-looking statements within the meaning of federal securities laws, wh...